In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

智通财经获悉，美国食品和药物管理局(FDA)周一批准了Hikma仿制诺和诺德(NVO.US)糖尿病药物Victoza，为该药物的另一种仿制药在美国上市扫清了道路。

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

智通财经获悉，美国食品和药物管理局 (FDA)周一批准了Hikma仿制诺和诺德 (NVO.US)糖尿病药物Victoza，为该药物的另一种仿制药在美国上市扫清了道路。Hikma的品牌仿制药将与Teva制药公司竞争，Teva制药公司今年早些时候在美国推出了Victoza的授权仿制药。

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options ...

【FDA批准首个用于治疗低血糖的GLP-1仿制药】财联社12月24日电，美国食品药品管理局（FDA）批准首个用于治疗低血糖的GLP-1仿制药。 批准首个提及VICTOZA的仿制药。 适用于改善糖尿病患者的血糖控制。

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...

Victoza is a brand-name subcutaneous injection that doctors prescribe to manage blood sugar and reduce the risk of certain cardiovascular events in people with type 2 diabetes. It contains the ...